RECURRENT HEAD AND NECK CANCER
Clinical trials for RECURRENT HEAD AND NECK CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT HEAD AND NECK CANCER trials appear
Sign up with your email to follow new studies for RECURRENT HEAD AND NECK CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple-drug cocktail takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New vaccine plus immunotherapy shows promise against HPV-Linked head and neck cancer
Disease control Recruiting nowThis trial tests whether adding a vaccine called BNT113 to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced head and neck cancer linked to HPV16. About 350 participants will receive either the combination or the standard single d…
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE2, PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Ultrasound boosts cancer drug in tiny trial
Disease control Recruiting nowThis early study tests whether using ultrasound and microbubbles can help the immunotherapy drug pembrolizumab (Keytruda) work better in people with head and neck cancer that has come back or spread. Only 6 participants will receive three rounds of treatment. The main goal is to …
Matched conditions: RECURRENT HEAD AND NECK CANCER
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC